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HEMOSTASIS, THROMBOSIS, AND VASCULAR BIOLOGY
Neuroserpin reduces cerebral infarct volume and protects neurons from
ischemia-induced apoptosis
Manuel Yepes, Maria Sandkvist, Mike K. K. Wong, TimothyA. Coleman, Elizabeth Smith, Stanley L. Cohan, and DanielA. Lawrence
Neuroserpin, a recently identiﬁed inhibi-
tor of tissue-type plasminogen activator
(tPA), is primarily localized to neurons
within the central nervous system, where
it is thought to regulate tPAactivity. In the
present study neuroserpin expression
and its potential therapeutic beneﬁts
were examined in a rat model of stroke.
Neuroserpinexpressionincreasedinneu-
ronssurroundingtheischemiccore(isch-
emic penumbra) within 6 hours of occlu-
sion of the middle cerebral artery and
remained elevated during the ﬁrst week
after the ischemic insult. Injection of
neuroserpin directly into the brain imme-
diately after infarct reduced stroke vol-
ume by 64% at 72 hours compared with
control animals. In untreated animals
both tPA and urokinase-type plasmino-
gen activator (uPA) activity was signiﬁ-
cantly increased within the region of
infarct by 6 hours after reperfusion.
Activity of tPA then decreased to control
levels by 72 hours, whereas uPA activity
continued to rise and was dramatically
increased by 72 hours. Both tPA and uPA
activity were signiﬁcantly reduced in
neuroserpin-treatedanimals.Immunohis-
tochemical staining of basement mem-
brane laminin with a monoclonal anti-
body directed toward a cryptic epitope
suggested that proteolysis of the base-
ment membrane occurred as early as 10
minutesafterreperfusionandthatintrace-
rebral administration of neuroserpin sig-
niﬁcantlyreducedthisproteolysis.Neuro-
serpin also decreased apoptotic cell
counts in the ischemic penumbra by
more than 50%. Thus, neuroserpin may
be a naturally occurring neuroprotective
proteinase inhibitor, whose therapeutic
administration decreases stroke volume
most likely by inhibiting proteinase activ-
ity and subsequent apoptosis associated
with focal cerebral ischemia/reperfusion.
(Blood. 2000;96:569-576)
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Introduction
Stroke is the second most common cause of death in the world after
heart disease and a leading cause of disability.1 It is estimated that
in the United States someone suffers a stroke about every minute
and a person dies of stroke about every 3.5 minutes.2 Various
strategies have been used to reduce stroke morbidity and mortality,
one of which has been thrombolysis with tissue-type plasminogen
activator (tPA) to restore cerebral blood ﬂow to ischemic brain
tissue. Thrombolysis with tPA produces arterial recanalization in
40% to 67% of patients3 and is associated with absolute improve-
ment in neurologic function after 90 days in 12% of the patients
treated within 3 hours of the onset of symptoms.4 However, in
seeming contradiction to these results, animal studies have demon-
strated that tPA-deﬁcient mice have a 41% decrease in stroke size
and a 61% increase in neuronal survival compared with wild-type
animals following occlusion of the middle cerebral artery (MCA).5
Although these results have been recently challenged,6,7 they have
also been reproduced by others.8 Furthermore, this latter study also
demonstrated that animals deﬁcient in plasminogen had an increase
in stroke volume, whereas animals deﬁcient in the primary plasmin
inhibitor, a2-antiplasmin, had a decrease in stroke size similar to
tPA null mice, suggesting a plasminogen-independent function for
tPAin cerebral ischemia.8
In both rats and mice, tPAexpression is increased by events that
require neuronal plasticity, such as synaptic remodeling, long-term
potentiation, kindling, and seizures.9-11 Expression of tPA is also
correlated with central nervous system (CNS) development and
maintenance, and in the modulation of cell-cell and cell-
extracellular matrix (ECM) interactions.12-14 As in stroke, tPA-
deﬁcient mice are protected from excitotoxin-induced neuronal
death. However, in contrast to stroke, plasminogen-deﬁcient mice
are also protected from excitotoxic injury,15-17 and it has been
suggested that tPA and plasminogen may promote excitotoxin-
induced neuronal death through proteolysis of the neuronal ECM.18
Following stroke there is a densely ischemic area where
neurons are irreversibly damaged, surrounded by an area known as
‘‘ischemic penumbra,’’ where cerebral blood ﬂow is sufficiently
decreased to abolish electrical potentials yet sufficient to allow
maintenance of membrane potentials and cellular ionic homeosta-
sis.19-21 This zone of penumbra has also been observed in magnetic
resonance image studies of rats in the area surrounding the necrotic
core.22-24 With time, this potentially salvageable area of penumbra,
or reversible ischemia, tends to become infarcted. In vivo microdi-
alysis has demonstrated that after cerebral ischemia there is a large
release of excitotoxins 25-28 not only in the infarcted core but also in
the area of ischemic penumbra,29 where the presence of apoptotic
cells has also been described.30-32 Because tPA may play an
signiﬁcant role in both excitotoxin- and ischemia-induced neuronal
degeneration,5,8,15-17,33 it is possible that an inhibitor of tPA might
play an important role in neuronal survival after stroke.
Neuroserpin is a recently identiﬁed member of the serine
Department of Biochemistry, American Red Cross Holland Laboratory, Rock-
ville, MD; Department of Protein Development, Human Genome Sciences Inc,
Rockville, MD; Department of Neurology, Georgetown University Medical
Center, Washington, DC.
Submitted November 18, 1999; accepted March 10, 2000.
Supported by National Institutes of Health Grants HL55374 and HL55747 to
D.A.L.
Reprints: Daniel A. Lawrence, Biochemistry Department, J. H. Holland
Laboratory, American Red Cross, 15601 Crabbs Branch Way, Rockville, MD
20855; e-mail: lawrenced@usa.redcross.org.
The publication costs of this article were defrayed in part by page charge
payment. Therefore, and solely to indicate this fact, this article is hereby
marked ‘‘advertisement’’in accordance with 18 U.S.C. section 1734.
r 2000 by TheAmerican Society of Hematology
BLOOD, 15 JULY 2000 x VOLUME 96, NUMBER 2 569proteinase inhibitor (serpin) gene family34,35 that reacts preferen-
tially with tPA, having a second-order rate constant for the
inhibition of tPA of 6.2 3 105 M21s21.36 Furthermore, neuroserpin
expression is primarily localized to regions of the brain where tPA
has been previously identiﬁed.36 The present study demonstrates
that neuroserpin is expressed in the area of ischemic penumbra in
an animal model of focal cerebral ischemia/reperfusion. Moreover,
intracerebral administration of neuroserpin after stroke decreases
stroke volume, reduces basement membrane proteolysis, and
diminishes the number of cells with apoptotic features in the area of
ischemic penumbra.Thus, the data presented suggest that neuroser-
pin, a selective, naturally occurring inhibitor of tPA, may play an
important role in neuronal survival after stroke.
Materials and methods
Animal preparation and surgery
Adult male Sprague-Dawley rats weighting 350 to 400 g were used.
Anesthesia was induced with 4% halothane, 70% nitrous oxide, and a
balance of oxygen and was maintained with 2% halothane and 70% nitrous
oxide during the surgical procedure. Rats were intubated endotracheally
and mechanically ventilated. Arterial blood pressure and blood gases were
monitored. Body temperature was maintained at 37.5 6 0.5°C with a
warming blanket (Animal Blanket Control Unit, Harvard Apparatus) and
controlled with a rectal thermistor and a probe inserted into the masseter
muscle. The MCA was exposed and cauterized with a microbipolar
coagulator (Non-Stick Bipolar Coagulation Forceps, Kirwan Surgical
Products, Marshﬁeld, MA) above its crossing point with the inferior
cerebral vein as described elsewhere.37 Animals were then placed on a
stereotactic frame and 20 µL of either 30 µmol/L active neuroserpin in
phosphate-buffered saline (PBS), 30 µmol/L inactive elastase-cleaved
neuroserpin in PBS, or 20 µLof PBS only was injected intracortically with a
Hamilton Syringe through the burr hole. Comparison of untreated animals
(no injection) to PBS-treated rats revealed no signiﬁcant difference in stroke
volume, indicating that the injection itself did not contribute to the infarct
size (data not shown). After the intracortical injections, the left common
carotid artery was exposed through a midline cervical incision and
temporarily occluded for 1 hour with a microaneurysm clip (8 mm, 100 g
pressure; Roboz Surgical Instruments, Rockville, MD).38 Animals were
then allowed to recover under the heating lamp, returned to their cages, and
given free access to water.
Infarct volume
Rats were anesthetized with pentobarbital intraperitoneally 72 hours after
infarction and brains were removed after transcardiac perfusion with PBS
and paraformaldehyde 4% (Fisher Scientiﬁc, HC-200).The entire brain was
embedded in paraffin and coronal sections, 20 µm thick, were cut through
the rostrocaudal extent of the brain (Figure 1). The sections were stained
with hematoxylin-eosin and using the NIH Image Analyzer System, the
total volume of each infarction was determined by the integration of the
areas of 8 chosen sections and the distances between them. The rostral and
caudal limits for the integration were set at the frontal and occipital poles of
the cortex.39 Statistical signiﬁcance between groups of animals was
identiﬁed by a Student t test.
TUNEL staining
Paraffin-embedded sections (5 µm) from neuroserpin- and control-treated
animalskilledat6,24,48,and72hoursafterreperfusionwereexaminedfor
TUNEL reactivity using the Apoptag Kit (Oncor, Gaithesburg, MD).
Paraffin sections were dewaxed, rehydrated, and treated with proteinase K
(20 µg/mL) and blocked for endogenous peroxidase activity with 3% H2O2.
Subsequent end-labeling was done with TdT enzyme at 37°C for 1 hour.
Anti-digoxigenin peroxidase conjugate was applied to the tissue for 30
minutes at room temperature. The slides were developed with peroxidase
substrate DAB for 5 minutes (Sigma, St Louis, MO), washed in dH2O for 5
minutes, and counterstained with 0.5% methyl green for 10 minutes. To
quantitate the presence of cells with apoptotic bodies, an area surrounding
the ischemic core extending from the cerebral cortex to the most anterior
(septal) part of the hippocampus was imaged in neuroserpin- and control-
treated animals. Histologic features used by light microscopy to identify
apoptosis depended on recognition of dark-brown rounded or oval apop-
totic bodies.40,41 Statistical signiﬁcance between groups of animals was
identiﬁed by a Student t test.
Zymography
For sodium dodecyl sulfate-polyacrylamide gel electrophoresis (SDS-
PAGE) zymography the region containing the stroke in brains from
neuroserpin- and PBS-treated animals killed at 6 and 72 hours after
reperfusion were dissected and slices of approximately 600 mg were frozen
in dry ice and stored at 270°C. A similar portion of brain was dissected
from the same area in the contralateral hemisphere in both neuroserpin-
treated and control animals. Protein extracts were prepared in 1.2 mL
extraction buffer as described.36 The protein concentration was then
determined, and 30 µg of extract (approximately 1 µL) was mixed with
nonreducing sample buffer and subjected to SDS-PAGE on a 10% gel
(Novex, San Diego, CA). Human tPA 0.3 ng (Genentech, San Francisco,
CA) and a rat kidney extract containing urokinase-type plasminogen
activator (uPA) prepared in the same way as the brain extracts were
included as positive controls and the identity of each PAwas determined by
including either anti-tPAor anti-uPAin the indicator ﬁlm (data not shown).
Following electrophoresis, the gel was soaked in 2.5% Triton X-100 for
2 3 45 minutes to remove the SDS. An indicator gel was prepared by
mixing 1.25 mLof an 8% solution of boiled and centrifuged milk in PBS, 5
mL PBS, and 3.75 mL of a 2.5% agar solution prewarmed at 50°C.
Figure 1. Rat brain sections 72 hours after reperfusion. Hematoxylin-eosin stain
of 3 representative sections from the same brain 72 hours after reperfusion. The
infarcted area is indicated with arrows, and the box indicates the location where
higher resolution analysis was performed (magniﬁcation 3 5).
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concentration of 30 µg/mL and the solution mixed and poured onto a
prewarmed glass plate. The Triton X-100 soaked gel was applied to the
surface of the plasminogen-milk indicator gel and incubated in a humid
chamber at 37°C. Milk indicator gel without plasminogen was also included
as a control. The relative increase of tPAand uPAipsilateral to the stroke at
6 hours after reperfusion was quantiﬁed by scanning a photograph of the
SDS-PAGE zymography gel taken at an early time of development, before
full lysis had occurred, and using the NIH ImageAnalyzer System. Normal
baseline PA activities were calculated from the average of the activity
present in 6 independent contralateral samples for which the coefficient of
variation was less than 0.2. Control analysis of puriﬁed tPA by this method
demonstrated that lysis was linear over at least an 8-fold range with a
correlation coefficient (r) of 0.994. Statistical signiﬁcance between groups
was identiﬁed by a Student t test.
For the in situ proteinase activity assay, brains from neuroserpin- and
control-treated animals killed at 6 and 72 hours after reperfusion (n 5 3 for
each condition at each time point) were frozen in optimal cutting
temperature compound (OCT) and stored at 270°C. Cryostat sections 8 µm
thick were examined for PA activity in overlays prepared as described.14
The overlay mixture (150 µL) was applied to prewarmed tissue sections and
spread under glass coverslips. Slides were incubated in a humid chamber at
37°C and developed. Control sections were overlaid with a milk agar
mixture without plasminogen. Other controls included those in which either
100 µg/mL anti-tPA(a generous gift of Tom Podor, MacMaster University)
or anti-uPA (Chemicon International, Temecula, CA) antibodies or 5
µmol/Lneuroserpin36 were included in addition to plasminogen.
Immunohistochemistry
All immunohistochemistry was performed on 5-µm deparaffinized-
embedded sections. The sections were ﬁrst immersed in methanol 0.3%
H2O2 for 30 minutes and then either preincubated directly with 10% serum
(either horse or goat) or ﬁrst treated with 0.04% pepsin in 0.1 N HCl for 20
minutes at 23°C before being blocked with serum. All sections were also
developed with the ABC reagent (Vector Laboratories, Burlingame, CA),
using the DAB chromogen for 4 minutes, after which the sections were
counterstained with Mayer’s hematoxylin for 1 minute. For neuroserpin
staining, adult male Sprague-Dawley rats that were not injected with
neuroserpin or PBS were killed 6, 24, 48, 72, 96, or 168 hours after bipolar
coagulation of the MCA, or sham operation, and sections were prepared as
above and stained with rabbit antihuman neuroserpin as described.36 For
tPA, uPA, and laminin, both control and neuroserpin-treated animals were
examined. For tPA, the sections were stained with affinity puriﬁed sheep
antihuman tPA(a generous gift fromTom Podor, MacMaster University), at
1:800 dilution after pepsin digestion. For uPA goat antihuman, uPA
(Chemicon International-AB767) was used at 1:200 dilution after pepsin
digestion. For laminin staining, a murine monoclonal antihuman laminin
(Chemicon International-MAB2920) was used at a 1:4000 dilution either
with or without pepsin digestion as above. For all immunohistochemical
analysis, n $ 2 for each condition at each time point except for neuroserpin
staining at 96 and 168 hours, for which n 5 1 each.
Results
Neuroserpin expression after stroke
Because tPA may contribute to neuronal death after cerebral
infarction, increased expression of neuroserpin might play an
important role in neuronal survival after stroke. To examine the
expression of neuroserpin after cerebral ischemia, immunohisto-
chemical staining of brain sections was performed at 6, 24, 48, 72,
96, and 168 hours after MCA occlusion and reperfusion. Figure 1
shows 3 representative brain sections harvested 72 hours after
reperfusion and stained with hematoxylin-eosin. The infarct is
clearly evident as the lighter stained tissue in the cortex of the left
hemisphere, and the box indicates the area where higher resolution
analysis was performed. Neuroserpin immunoreactivity was in-
creased in the area surrounding the ischemic core (penumbra) and
in the ipsilateral hippocampus as early as 6 hours after stroke and
remained elevated up to 168 hours when compared with the
contralateral, nonischemic hemisphere or with sham-operated
controls (data not shown).The peak of neuroserpin immunoreactiv-
ity in both the number of neuroserpin-positive cells and in the
intensity of the staining appeared to be at 48 hours following
reperfusion (Figure 2). The apparent rapid increase in neuroserpin
expression following infarction suggests that the surrounding
surviving cells may be up-regulating neuroserpin expression in
response to the ischemic insult.
Effect of neuroserpin on stroke volume
To see if neuroserpin could reduce neuronal cell death after stroke
with subsequent preservation of normal brain tissue, neuroserpin
was administered intracerebrally immediately following MCA
occlusion. Comparison of stroke volume between control and
neuroserpin-treated animals 72 hours after reperfusion indicated
that intracortical injection of 30 µmol/Lneuroserpin reduced stroke
size by 64%, from 161 mm3 in control animals to 58 mm3 in
neuroserpin-treated animals (Figure 3). In contrast, stroke volume
in animals treated with inactive neuroserpin, cleaved in its reactive
center loop, showed no decrease in stroke size relative to control
animals, suggesting that active neuroserpin is required to reduce
stroke volume (Figure 3).
Proteinase activity after stroke
The fact that only the active inhibitory form of neuroserpin reduced
stroke volume suggests that neuroserpin acts primarily by blocking
proteinase activity, possibly tPA activity.36 To examine proteinase
activity following stroke, and to determine the effect of neuroserpin
treatment on proteinase activity, 2 different assays were used. The
ﬁrst, SDS-PAGE zymography was performed on extracts of tissues
dissected from the cortex, either ipsilateral or contralateral to the
stroke of both PBS- and neuroserpin-treated animals (Figure 4A).
After electrophoresis and removal of SDS, the gels were overlaid
onto milk-agarose gels with or without plasminogen. In the absence
of plasminogen no proteinase activity could be detected in any of
the extracts, whereas addition of plasminogen to the milk-agarose
mixture demonstrated that both tPA and uPA activity were present
in all cortex extracts examined, including those from sham-
operated animals (data not shown). Examination of extracts
Figure 2. Immunohistochemical staining of neuroserpin in brain 48 hours after
reperfusion. Panel A shows the area of penumbra, panel B shows a similar area of
the cortex contralateral to the stroke and panels C and D show the hippocampus.
Panels A and C are ipsilateral to the stroke and panels B and D are contralateral
(magniﬁcation 3 100 inAand B and 3 40 in C and D).
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both tPA and uPA activity were elevated ipsilateral to the stroke in
PBS-treated animals but that only uPA appeared to be elevated in
neuroserpin-treated brains (Figure 4A). However, by 72 hours tPA
activity appeared to return to baseline, indicating that the increase
in tPA activity is transient and that neuroserpin can reduce the
extent of this increase. In contrast, uPA-catalyzed activity, which
was relatively low in the 6-hour extracts, increased dramatically in
ipsilateral extracts of animals killed 72 hours after reperfusion, and
this increase was apparent in both control and neuroserpin-treated
brains. However, like both tPA and uPA at 6 hours, the amount of
uPA activity at 72 hours was signiﬁcantly lower in neuroserpin-
treated animals compared to controls (Figure 4A). Quantitative
image analysis of these data indicated that by 6 hours following
reperfusion ipsilateral to the stroke in PBS-treated animals there
was an approximately 50% increase in tPA activity and an
approximately 125% increase in uPA activity relative to baseline
levels (Figure 4B). However, in neuroserpin-treated animals the
increase of both PAs ipsilateral to the stroke was markedly reduced,
showing only an approximately 50% increase for uPA and no
signiﬁcant increase in tPAcompared to baseline levels (Figure 4B).
These results indicate that there is an early and transient increase in
tPA activity ipsilateral to the stroke and that neuroserpin is able to
block this increase. Similarly, there is an early increase in uPA
activity ipsilateral to the stroke, but in contrast to tPA this increase
is not transient and continues to rise at least up to 72 hours after
reperfusion, and is not blocked by treatment with neuroserpin but is
only reduced compared to the PBS-treated animals.
To examine the distribution of proteinase activity within the
brains of the PBS- and neuroserpin-treated animals, in situ
zymography of frozen brain sections was performed. These data
demonstrate that, like the SDS-PAGE zymography, all of the
proteolytic activity detected in both control and neuroserpin-treated
brains was plasminogen dependent, because no proteinase activity
was observed in the absence of plasminogen (Figure 5A,D). At 6
hours after reperfusion, proteinase activity in all sections was
primarily associated with the meningeal tissues of both ipsilateral
and contralateral sides. This activity was also completely blocked
by the addition of anti-tPA antibodies, indicating that the majority
of PA activity within the brain at this time is tPA (data not shown).
In contrast, by 72 hours after reperfusion, there was a large increase
in plasminogen-dependent proteolytic activity ipsilateral to the
stroke in control animals (Figure 5B), and unlike the sections at 6
hours or the 72 hours contralateral side, this activity was not
restricted to the meninges and was not completely blocked by the
addition of anti-tPA antibodies to the plasminogen overlay (arrows
in Figure 5B,C). In neuroserpin-treated animals this zone of
proteinase activity was signiﬁcantly smaller than in the untreated
animals (Figure 5E,F). This suggests that by 72 hours much of the
plasminogen-dependent activity within the region of the stroke was
not tPA. Consistent with this, the addition of anti-uPAantibodies to
the plasminogen overlay markedly reduced proteolysis within the
area of the stroke while having no effect on the proteolytic activity
in the meningeal tissues contralateral to the stroke (data not
shown). This implies that within the area of the infarct at 72 hours
following reperfusion there is a signiﬁcant increase in uPAactivity.
These results also suggest that there is not a large up-regulation of
either tPA or uPA immediately following stroke; however, by 72
hours after reperfusion, uPA-catalyzed proteolysis is signiﬁcantly
increased speciﬁcally within the region of the infarct. These results
are also consistent with the SDS-PAGE zymography and suggest
that the lesser increase in uPA activity observed by SDS-PAGE
zymography in neuroserpin-treated animals may simply reﬂect the
smaller size of the infarct in this group and not a direct inhibition of
the up-regulation of uPA-activity by neuroserpin.
Immunohistochemical staining for tPAindicated that by 6 hours
after reperfusion, tPAantigen was detected only within the vascular
endothelial cells and not within neuronal cells (Figure 5G).
Consistent with the relatively low levels of uPAactivity at 6 hours,
no uPA staining could be detected in these sections (data not
shown). However, by 72 hours after reperfusion, uPAimmunoreac-
tivity was readily detected, but only in the area of ischemic
penumbra (Figure 5H). This is consistent with the in situ zymogra-
phy analysis demonstrating uPA activity predominantly within the
cortex and only at 72 hours after reperfusion. Finally, at 72 hours in
neuroserpin-treated animals, there was a marked reduction in the
overall area where uPAantigen was detected but not in the intensity
of the staining, compared to PBS-treated animals (data not shown).
This further suggests that the reduced uPA activity observed by
Figure 3. Quantitative analysis of infarct volume 72 hours after reperfusion.
Quantitation of the stroke volume was performed as described in ‘‘Materials and
methods.’’PBS indicates animals injected with PBS (n 5 8); Ns, animals injected with
neuroserpin (n 5 8); Cl-Ns, animals injected with elastase-cleaved inactive neuroser-
pin (n 5 2). P values relative to the PBS-treated animals , .01 are shown, and errors
represent SEM.
Figure 4. SDS-PAGE zymography of brain extracts. (A) SDS-PAGE zymography
of brain extracts. Lane 1 is human tPA, lane 2 is a rat kidney extract as a marker for rat
uPA, lanes 3 through 6 are extracts of brain 6 hours after reperfusion, and lanes 7
through 10 are extracts 72 hours after reperfusion. Lanes 3 and 7 are ipsilateral to the
infarct of PBS- treated animals, lanes 4 and 8 are contralateral to the infarct. Lanes 5
and 9 are ipsilateral to the infarct in neuroserpin-treated animals and lanes 6 and 10
are contralateral. (B) Quantitative image analysis of PA activity from SDS-PAGE
zymography of brain extracts 6 hours following reperfusion. The results represent the
average fold increase in either tPA or uPA activity ipsilateral to the stroke relative to
normal baseline PA activities contralateral to the stroke. PBS and Ns represent
animals treated with either PBS or neuroserpin, respectively, and n $ 3 for each
condition tested. P # .05 relative to the contralateral activity are shown, and errors
represent SEM.
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neuroserpin-treated animals.
Basement membrane degradation after cerebral ischemia
Because excitotoxin-induced laminin degradation has been sug-
gested to be mediated by tPAand to precede apoptotic cell death,18
we examined the effect of stroke on laminin immunoreactivity. For
this analysis we used a monoclonal antibody that does not react
strongly with rat laminin in ﬁxed tissue unless the tissue is ﬁrst
proteolyzed to expose cryptic laminin epitopes. This is shown in
Figure 6 panels A and B, where panel A shows a section of
unproteolyzed rat cortex reacted with the antibody and panel B
shows an adjacent section that was ﬁrst treated with proteinase in
vitro before reaction with the antibody. These results indicate that
in the absence of proteolysis this antibody does not react with
vascular laminin. However, after proteolysis there is a strong
reaction that appears to be localized to the vessels. Thus, this
antibody provides an excellent tool to probe for partial proteolysis
of the basement membrane within ﬁxed brain tissue. Examination
of laminin staining in cortical tissue as early as 10 minutes after
reperfusion indicated that even at this early time there was
apparently signiﬁcant proteolysis of the basement membrane in
control animals (Figure 6C). However, in neuroserpin-treated
animals the extent of laminin proteolysis was signiﬁcantly reduced
such that only slight staining of the vascular laminin was apparent
(Figure 6D).This latter result was not due to the absence of laminin
in this tissue because treatment of the sections with proteinase in
vitro yielded staining indistinguishable from that shown in Figure
6B (data not shown). Vascular laminin staining was also observed
at 6 hours after reperfusion in control animals and, similar to the
results at 10 minutes, treatment with neuroserpin signiﬁcantly
reduced this staining (Figure 6E,F). Furthermore, by 6 hours after
reperfusion laminin staining was also observed within neurons in
the area of cerebral ischemia and, as with vascular laminin staining,
was reduced by neuroserpin treatment (Figure 6E,F). The neuronal
staining most likely represents new synthesis of laminin because in
control animals not subjected to stroke no laminin staining was
observed in neurons either with or without proteinase treatment
(Figure 6A,B). Laminin staining remained strong at 24 and 48
hours, but started to decrease by 72 hours. Also, at each time point
the neuroserpin-treated animals showed signiﬁcantly less immuno-
reactivity than control animals (data not shown). These data
suggest that there is a very early proteolytic event that appears to
act on the vascular basement membrane and that neuroserpin
treatment is able to reduce this proteolysis.
Apoptosis
Because cerebral ischemia has been suggested to induce apoptosis
in the ischemic penumbra, a good therapeutic strategy aimed at
reducing cell death after stroke should target the recovery of cells in
this area. To see if neuroserpin reduced infarct volume by
preventing penumbral apoptosis, tissue from untreated and neuro-
serpin-treated animals was stained by the TUNEL method (Figure
7A-C). The extent of apoptosis in these sections was then
quantiﬁed as described above and these data are shown in Figure 7,
panel D. The number of cells within a deﬁned area of the penumbra
with apoptotic bodies after 72 hours of cerebral ischemia was
22 6 5 in untreated animals and decreased to 8 6 2 in neuroserpin-
treated animals (Figure 7D). This indicates that neuroserpin
signiﬁcantly inhibits penumbral apoptosis. To see if neuroserpin
also blocked cell death at earlier times, apoptosis was also
quantiﬁed at 6, 24, and 48 hours. These data indicate that at all
times examined apoptosis was reduced by at least 50% with
neuroserpin treatment (Figure 7E). Finally, to test if neuroserpin
had a direct effect on apoptosis, 2 independent assays were
performed. In the ﬁrst, neuroserpin was tested for its ability to
block T-cell receptor-mediated apoptosis of a T-cell hybridoma in
vitro.42 In the second assay, neuroserpin was tested for its ability to
directly inhibit caspase activity in extracts of B lymphoma cells
treated with anti-Fas IgG to induce apoptosis and caspase activa-
tion.43 In both assays neuroserpin had no effect on either apoptosis
or caspase activity (data not shown). Taken together, these results
Figure 5. In situ zymography and immunohistochemical staining of brain
sections. In situ zymography in panels A-F; panels A and D are developed without
plasminogen, and all other panels are developed with plasminogen. Panels C and F
also contain anti-tPA antibodies. The white arrows indicate the area of the infarct
(magniﬁcation 3 3). (G) Immunohistochemical staining of tPA 6 hours after reperfu-
sion. The black arrows indicate tPA-positive blood vessels. (H) Immunohistochemical
staining of uPAin the area of penumbra 72 hours after reperfusion (magniﬁcation in G
and H 3 400).
Figure 6. Immunohistochemical staining of laminin. PanelsAand B show normal
cortex in an animal without stroke. Panel A was developed with anti-laminin but
without pretreatment in vitro of the section with proteinase. Panel B is an adjacent
section with in vitro proteinase treatment. Panels C to F are from stroked animals and
developed with antilaminin and no proteinase treatment. Panels C and D are 10
minutes after reperfusion and panels E and F are 6 hours after reperfusion. Panels C
and E represent PBS-treated and panels D and F neuroserpin-treated animals
(magniﬁcation 3 100).
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therefore, it is likely that neuroserpin blocks events before induc-
tion of apoptosis.
Discussion
Neuroserpin, a natural inhibitor of tPA, is found almost exclusively
within the CNS36 and shows an early and signiﬁcant increase in its
expression within the area of ischemic penumbra in response to
stroke (Figure 2). Cerebral ischemia induces neuronal depolariza-
tion44 and releases excitotoxins,29 which in turn triggers the release
of tPA.45,46 Because tPAmay be associated with increased neuronal
loss in response to both ischemia and excitotoxins,5,8,15,33 the
increased local expression of neuroserpin following ischemia may
represent an innate protective response to elevated tPA levels and
suggests that neuroserpin may be a naturally occurring neuronal
survival factor. Consistent with this hypothesis, neuroserpin treat-
ment resulted in a signiﬁcant decrease in stroke volume relative to
control animals. Furthermore, only functionally active neuroserpin
was able to reduce infarct size, suggesting that inhibition of
proteinase activity was necessary for the neuroprotective effects of
neuroserpin (Figure 3).
Zymographic analysis of brain extracts at 6 and 72 hours after
reperfusion indicated that there was an early rise in both tPA and
uPA activity in the area of the infarct in control animals and that
treatment with neuroserpin signiﬁcantly reduced these activities
(Figure 4). These data are similar to earlier results that reported an
increase in uPA activity in both rats and mice following cerebral
ischemia47,48 and to at least 1 other study that reported a signiﬁcant
increase in tPA activity.5 However, in 2 studies tPA activity after
stroke was reported to be either decreased47 or unchanged.48 The
apparent difference in the activity of tPA noted here compared to
these earlier studies may in part reﬂect the time after cerebral
ischemia when tPAwas measured because our data suggest that the
increase in tPAactivity is transient and because none of these other
studies measured tPA at 6 hours following reperfusion. These
differences might also be due to the different animal models used in
the various studies. For example, the model used here37,49 creates a
permanent occlusion of the middle cerebral artery at its crossing
point with the inferior cerebral vein with reperfusion provided by
temporary clamping of the left carotid artery. This produces an
ischemic injury in a well-deﬁned area of the cerebral cortex (Figure
1), and in contrast to the intravascular ﬁlament model,50 avoids the
potential of large lesions to the vascular endothelium and severe
disruption of the blood-brain barrier that could lead to signiﬁcant
changes in the local tPAactivity. Nonetheless, our results and those
of Wang et al5 suggest that there is an early local increase in tPA
activity in the area of the infarct, and the data reported here further
suggest that this increase is transient. Because treatment with
functionally active neuroserpin reduced both the local increase in
tPA activity as well as the infarct size, it is possible that these
2 effects are related and that by blocking the action of tPA very
early after reperfusion the later increase of the infarcted area
is prevented.
In contrast to tPA, uPAactivity increased to very high levels by
72 hours following reperfusion and was localized almost exclu-
sively to the ischemic penumbra (Figures 4 and 5). The role of uPA
after cerebral ischemia is largely unknown. However, because the
necrotic core is already well deﬁned by 72 hours after the stroke, it
is unlikely that the late increase in uPA activity plays an important
role in the development of the infarct. This inference is also
consistent with a recent study of stroke in uPA-deﬁcient mice that
indicated that there was no difference in infarct volume between
wild-type and uPA2/2 mice 24 hours after reperfusion.8 However,
because uPA has been demonstrated in both glial cells during
myelination and in mature cortical neurons,51 the late expression of
uPA activity and antigen suggests that uPA could participate in the
process of neuronal recovery after stroke as was suggested by
Rosenberg et al.47
Although the role of tPAactivity in infarct evolution is not well
understood, tPA-induced plasmin cleavage of basement membrane
laminin has been suggested to play a role in excitotoxin-induced
neuronal death within the hippocampus18 and in the disappearance
of basement membrane antigens following ischemia and reperfu-
sion.52 The basement membrane is a specialized part of the ECM
that connects the endothelial cell compartment to the surrounding
cell layers.53 Laminins are important components of the basement
membrane, playing a pivotal role in cell-ECM interactions, includ-
ing promotion of neurite outgrowth, cell attachment, proliferation,
and differentiation, as well as in the development and regeneration
of the CNS.54-58 In the present study exposure of cryptic laminin
epitopes within the basement membrane was observed within 10
minutes of reperfusion, suggesting that there is proteolytic activity
acting on the basement membrane very early following cerebral
ischemia (Figure 6). Like the observed increase in tPA, this activity
appears to be transient with peak epitope exposure occurring within
6 to 24 hours of reperfusion. Whether this effect is due to the direct
action of tPA on laminin, is mediated through plasmin as has been
suggested,18 or involves matrix metalloproteinases (MMPs)59 or
other as yet unidentiﬁed proteinases is not clear. Regardless of
which proteinase is responsible for the apparent basement mem-
brane degradation, the extent of laminin epitope expression was
signiﬁcantly decreased in neuroserpin-treated animals (Figure 6).
This suggests that neuroserpin is inhibiting the proteolytic attack
on the basement membrane, most likely by inhibiting tPA. Thus,
Figure 7. Neuronal apoptosis within the ischemic penumbra. TUNEL staining
ipsilateral of the infarct in PBS-treated (panels A and B) and neuroserpin-treated
(panel C) animals. In panelA, NC indicates the necrotic core and P indicates the area
of the penumbra. Panels B and C are high magniﬁcation images of the penumbra in
control (panel B) and neuroserpin-treated animals (panel C). Examples of cells
considered to be apoptotic for the purposes of quantiﬁcation are indicated with the
open arrows; cells considered as necrotic are indicated with the closed arrows.
Magniﬁcation in panel A is 3 40 and in panels B and C 3 400. (D) Quantitative
analysis of apoptosis in the area of penumbra 72 hours after reperfusion. Quantitation
was performed as described in ‘‘Materials and methods’’and only cells with apoptotic
bodies present (panel B) were counted. Control represents animals injected with PBS
(n 5 6). Neuroserpin indicates animals injected with neuroserpin (n 5 6). P values ,
.05 are shown, and errors represent SEM. (E) Quantitation of apoptosis was
performed as in panel D at the times indicated, (s) PBS-treated animals, (h)
neuroserpin-treated animals.
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able to preserve the integrity of the basement membrane and thus
the blood-brain barrier after stroke.
It is known that disruption of cell-matrix interactions can lead to
apoptosis.60,61 Because the cryptic laminin epitopes were observed
as early as 10 minutes after reperfusion, with high levels of
neuronal expression seen by 6 hours (Figure 6), well before 24 to
48 hours, the peak of apoptosis (Figure 7E), the proteolytic disruption of
the basement membrane may be the trigger that initiates the program
of apoptotic neuronal cell death. Thus, the capacity of active
neuroserpin to block tPA-induced degradation of the basement
membrane may explain the ability of neuroserpin treatment to reduce
neuronal apoptosis by nearly 70% (Figure 7D). Finally, although it has
been demonstrated that apoptotic cell death in stroke is mediated by
proteinases known as caspases,62-64 neuroserpin failed to inhibit
either caspase activity orT-cell apoptosis, suggesting that neuroser-
pin is not an inhibitor of apoptosis per se and does not directly
block caspase activation or activity.
Intraneuronal laminin-like immunoreactivity has been reported
in both the developing and adult CNS,33,65,66 and in astrocytes after
transient ischemia.67 Laminin has also been shown to promote
neurite outgrowth.55We observed morphologically healthy neurons
that were positive for intracellular laminin staining in the area of
penumbra in control animals by 6 hours after reperfusion (Figure
6E), suggesting a role for intraneuronal laminin in neuronal
maintenance following ischemia. It is possible that synthesis of
laminin by neurons is in response to laminin degradation within the
basement membrane and that neuroserpin treated animals show
fewer laminin-positive cells because there is less basement mem-
brane degradation and thus many fewer distressed cells. It is
interesting to note that the region of the cortex that shows many
laminin-positive cells at 6 hours after reperfusion is the same
region that shows many apoptotic cells at 48 hours. This suggests
that if laminin expression is an early marker for cell distress then
neuroserpin treatment must be acting very early in the pathway that
leads to neuronal apoptosis.
Taken together the data presented here suggest a model for
stroke-induced neuronal death within the ischemic penumbra and
demonstrate the potential therapeutic beneﬁts of neuroserpin in this
setting. We speculate that one of the ﬁrst potentially deleterious
events to occur is the release of tPA by the vascular endothelial
cells in response to the acute ischemia. If there is also increased
vascular permeability at this time as a result of damage to the
blood-brain barrier,68 then this will allow tPA to cross from the
lumen of the vessel into the subvascular space, where it can bind
directly to laminin.69 This inappropriately targeted tPA can then,
either by itself or in concert with other proteinases such as plasmin
or MMPs,59,70 begin to degrade the basement membrane.This leads
to a further increase in vascular permeability, which in turn may
accelerate the degradation of the blood-brain barrier. In addition,
neuronal cells that are also dependent on the integrity of the
basement membrane may begin to lose their contacts with the
substrate, which in itself might induce a program of apoptosis as
has been described for other cell types.60 Our data also suggest that
by approximately 72 hours after the stroke onset the basement
membrane degradation and neuronal apoptosis have decreased,
stabilizing the lesion. At this time other factors such as uPA are
up-regulated possibly as part of the recovery process. Neuroserpin
treatment, by blocking the early effects of proteinase activity, may
help to maintain the integrity of the basement membrane, prevent-
ing further passage of tPAor other potentially harmful blood-borne
factors to the subvascular space. Neuroserpin may also directly
prevent neuronal loss by helping to preserve neuronal contacts to
thebasementmembrane.Furtherstudiesoftheefficacyofneuroser-
pin in the treatment of acute stroke will certainly clarify and reﬁne
this possible model.
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